VEGFA and cancer: On the other hand, current clinical trials for cancer treatment are in progress for several protein scaffolds, of which the following molecules are examples: BMS-986089 (myostatin inhibitor), 18F-BMS986192 (PD-L1 PET tracer), ABY-025 (anti-HER2 affibody), ABY-029 (anti-EGFR affibody), PRS-050 (VEGF-A antagonist), PRS-343 (target HER2), MP0112 (VEGF inhibitor), MP0250 (VEGF and HGF inhibitor), and MP0274 (target HER2) [97].